CN105164123A - (1s)-1-[5-({3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的结晶形式 - Google Patents

(1s)-1-[5-({3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的结晶形式 Download PDF

Info

Publication number
CN105164123A
CN105164123A CN201380065864.5A CN201380065864A CN105164123A CN 105164123 A CN105164123 A CN 105164123A CN 201380065864 A CN201380065864 A CN 201380065864A CN 105164123 A CN105164123 A CN 105164123A
Authority
CN
China
Prior art keywords
pyridin
amg151
methylpyridin
oxy
thiadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380065864.5A
Other languages
English (en)
Chinese (zh)
Inventor
S.阿塞林
L.布雷特
Y.陈
D.T.科森
A.科斯比
R.法雷尔
I.W.古纳沃达纳
J.黄
J.W.莱恩
D.莱
C.M.林德曼
V.卢乌
C.G.曼尼拉
R.米尔本
H.莫里森
H.坦
J.特德罗
D.J.沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Array Biopharma Inc
Original Assignee
Amgen Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Array Biopharma Inc filed Critical Amgen Inc
Publication of CN105164123A publication Critical patent/CN105164123A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380065864.5A 2012-11-09 2013-11-08 (1s)-1-[5-({3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的结晶形式 Pending CN105164123A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261724497P 2012-11-09 2012-11-09
US61/724,497 2012-11-09
PCT/US2013/069331 WO2014074940A1 (en) 2012-11-09 2013-11-08 Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol

Publications (1)

Publication Number Publication Date
CN105164123A true CN105164123A (zh) 2015-12-16

Family

ID=49753457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380065864.5A Pending CN105164123A (zh) 2012-11-09 2013-11-08 (1s)-1-[5-({3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的结晶形式

Country Status (6)

Country Link
US (1) US20150299182A1 (https=)
EP (1) EP2917213A1 (https=)
JP (1) JP2015536993A (https=)
CN (1) CN105164123A (https=)
CA (1) CA2890852A1 (https=)
WO (1) WO2014074940A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601586B (zh) * 2016-01-16 2017-10-20 陈洪国 一种治疗乙肝的药物组合物
CN111220614B (zh) * 2018-11-27 2023-05-09 宝山钢铁股份有限公司 一种快速评估钢水质量的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369081B1 (en) * 1999-01-22 2002-04-09 The University Of Toledo Muscarinic receptor agonists
CN101868459A (zh) * 2007-09-21 2010-10-20 阿雷生物药品公司 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1，2，4-噻二唑衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2457207C2 (ru) * 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369081B1 (en) * 1999-01-22 2002-04-09 The University Of Toledo Muscarinic receptor agonists
CN101868459A (zh) * 2007-09-21 2010-10-20 阿雷生物药品公司 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1，2，4-噻二唑衍生物

Also Published As

Publication number Publication date
WO2014074940A1 (en) 2014-05-15
JP2015536993A (ja) 2015-12-24
EP2917213A1 (en) 2015-09-16
CA2890852A1 (en) 2014-05-15
WO2014074940A9 (en) 2014-08-07
US20150299182A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US12071429B2 (en) Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
TW202436291A (zh) 心肌節抑制劑
TWI808305B (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
TW200815423A (en) Hetero compound
TW201819378A (zh) 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
US20220106287A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
EA026692B1 (ru) Стимуляторы sgc
CN120957993A (zh) 杂环glp-1激动剂
CN109476665A (zh) 取代的二氮杂杂双环化合物及其用途
CA3080402A1 (en) Aminoimidazopyridazines as kinase inhibitors
CA3255313A1 (en) MYST FAMILY INHIBITORS OF LYSINE ACETYLTRANSFERASE
TW202435857A (zh) 具有glp-1促效劑活性之化合物之鹽及固體形式
TW202521528A (zh) 化合物、組合物及方法
EP4705296A1 (en) Heteroarylindole inhibitors of apol-1
CN105164123A (zh) (1s)-1-[5-({3-[(2-甲基吡啶-3-基)氧基]-5-(吡啶-2-基硫基)吡啶-2-基}氨基)-1,2,4-噻二唑-3-基]乙烷-1,2-二醇的结晶形式
RU2794333C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
RU2797295C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK40082646A (en) Intermediates of isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
TW202508562A (zh) 雜環ｇｌｐ－１促效劑
HK1250715B (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151216